Cargando…

Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival

INTRODUCTION: Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome resulting in the fusion between the BCR gene, located on chromosome 22, and the ABL gene on chromosome 9. The prognostic significance of BCR-ABL transcript variants in CML is controversial. The aim of the curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Laabidi, Baraa, Slama, Nader, Ouahchi, Ines, Boufrikha, Wiem, Laatiri, Mohamed Adnene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371782/
https://www.ncbi.nlm.nih.gov/pubmed/37521582
http://dx.doi.org/10.1016/j.lrr.2023.100373
_version_ 1785078224941744128
author Laabidi, Baraa
Slama, Nader
Ouahchi, Ines
Boufrikha, Wiem
Laatiri, Mohamed Adnene
author_facet Laabidi, Baraa
Slama, Nader
Ouahchi, Ines
Boufrikha, Wiem
Laatiri, Mohamed Adnene
author_sort Laabidi, Baraa
collection PubMed
description INTRODUCTION: Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome resulting in the fusion between the BCR gene, located on chromosome 22, and the ABL gene on chromosome 9. The prognostic significance of BCR-ABL transcript variants in CML is controversial. The aim of the current study was to evaluate the clinico-hematological presentation and evolution of the disease, response to treatment and survival according to transcript type in chronic phase CML patients. RESULTS: The median age of our population was 50 years with a slight female predominance (sex-ratio 0.78). Sixty percent had the b3a2 transcript and 34% had the b2a2 type. Patients with the co-expression of these two transcripts (4.5%) and those with e19a2 were excluded from the analysis. Patients with b3a2 subtype were associated significantly with thrombocytosis (p = 0.006) and higher Sokal score (p = 0.038) compared to those with b2a2 transcript. The two isolated transcripts were not significantly associated with gender, age group, blast cell percentage or the identified ranges of spleen size. Complete cytogenetic response at 12 months for b3a2 patients and b2a2 patients was 78.6% and 21.4% respectively. This difference was statistically significant (p = 0.001, HR = 9.5, 95% CI 6.5–13.7). Patients with b3a2 transcript had a higher rate of optimal molecular response at 3 months (p = 0.04, HR = 4.2, 95% CI 1–17.3) and major molecular response at 12 months (p = 0.004, HR = 4.9, 95%CI 1.5–15.1). At the date of last follow-up, most patients achieving deep molecular response (MR4 or deeper) belonged to b3a2 group (79%) (p = 0.003, HR = 5.2, 95% CI 1.6–16.4). We did not find a significant difference in OS and EFS between the two groups. CONCLUSION: Our study concluded that b2a2 transcript is a prognostic factor in cytogenetic and molecular response but further studies are needed to complete this aspect.
format Online
Article
Text
id pubmed-10371782
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103717822023-07-28 Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival Laabidi, Baraa Slama, Nader Ouahchi, Ines Boufrikha, Wiem Laatiri, Mohamed Adnene Leuk Res Rep Article INTRODUCTION: Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome resulting in the fusion between the BCR gene, located on chromosome 22, and the ABL gene on chromosome 9. The prognostic significance of BCR-ABL transcript variants in CML is controversial. The aim of the current study was to evaluate the clinico-hematological presentation and evolution of the disease, response to treatment and survival according to transcript type in chronic phase CML patients. RESULTS: The median age of our population was 50 years with a slight female predominance (sex-ratio 0.78). Sixty percent had the b3a2 transcript and 34% had the b2a2 type. Patients with the co-expression of these two transcripts (4.5%) and those with e19a2 were excluded from the analysis. Patients with b3a2 subtype were associated significantly with thrombocytosis (p = 0.006) and higher Sokal score (p = 0.038) compared to those with b2a2 transcript. The two isolated transcripts were not significantly associated with gender, age group, blast cell percentage or the identified ranges of spleen size. Complete cytogenetic response at 12 months for b3a2 patients and b2a2 patients was 78.6% and 21.4% respectively. This difference was statistically significant (p = 0.001, HR = 9.5, 95% CI 6.5–13.7). Patients with b3a2 transcript had a higher rate of optimal molecular response at 3 months (p = 0.04, HR = 4.2, 95% CI 1–17.3) and major molecular response at 12 months (p = 0.004, HR = 4.9, 95%CI 1.5–15.1). At the date of last follow-up, most patients achieving deep molecular response (MR4 or deeper) belonged to b3a2 group (79%) (p = 0.003, HR = 5.2, 95% CI 1.6–16.4). We did not find a significant difference in OS and EFS between the two groups. CONCLUSION: Our study concluded that b2a2 transcript is a prognostic factor in cytogenetic and molecular response but further studies are needed to complete this aspect. Elsevier 2023-05-26 /pmc/articles/PMC10371782/ /pubmed/37521582 http://dx.doi.org/10.1016/j.lrr.2023.100373 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Laabidi, Baraa
Slama, Nader
Ouahchi, Ines
Boufrikha, Wiem
Laatiri, Mohamed Adnene
Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title_full Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title_fullStr Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title_full_unstemmed Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title_short Chronic-phase chronic myeloid leukemia: Incidence of BCR/ABL transcript and its correlation with presenting features, response to treatment, and survival
title_sort chronic-phase chronic myeloid leukemia: incidence of bcr/abl transcript and its correlation with presenting features, response to treatment, and survival
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371782/
https://www.ncbi.nlm.nih.gov/pubmed/37521582
http://dx.doi.org/10.1016/j.lrr.2023.100373
work_keys_str_mv AT laabidibaraa chronicphasechronicmyeloidleukemiaincidenceofbcrabltranscriptanditscorrelationwithpresentingfeaturesresponsetotreatmentandsurvival
AT slamanader chronicphasechronicmyeloidleukemiaincidenceofbcrabltranscriptanditscorrelationwithpresentingfeaturesresponsetotreatmentandsurvival
AT ouahchiines chronicphasechronicmyeloidleukemiaincidenceofbcrabltranscriptanditscorrelationwithpresentingfeaturesresponsetotreatmentandsurvival
AT boufrikhawiem chronicphasechronicmyeloidleukemiaincidenceofbcrabltranscriptanditscorrelationwithpresentingfeaturesresponsetotreatmentandsurvival
AT laatirimohamedadnene chronicphasechronicmyeloidleukemiaincidenceofbcrabltranscriptanditscorrelationwithpresentingfeaturesresponsetotreatmentandsurvival